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Abstract
Background: Of late, high-throughput microarray and sequencing data have been
extensively used to monitor biomarkers and biological processes related to many
diseases. Under this circumstance, the support vector machine (SVM) has been
popularly used and been successful for gene selection in many applications. Despite
surpassing benefits of the SVMs, single data analysis using small- and mid-size of data
inevitably runs into the problem of low reproducibility and statistical power. To address
this problem, we propose a meta-analytic support vector machine (Meta-SVM) that can
accommodate multiple omics data, making it possible to detect consensus genes
associated with diseases across studies.
Results: Experimental studies show that the Meta-SVM is superior to the existing
meta-analysis method in detecting true signal genes. In real data applications, diverse
omics data of breast cancer (TCGA) and mRNA expression data of lung disease
(idiopathic pulmonary fibrosis; IPF) were applied. As a result, we identified gene sets
consistently associated with the diseases across studies. In particular, the ascertained
gene set of TCGA omics data was found to be significantly enriched in the ABC
transporters pathways well known as critical for the breast cancer mechanism.
Conclusion: The Meta-SVM effectively achieves the purpose of meta-analysis as jointly
leveraging multiple omics data, and facilitates identifying potential biomarkers and
elucidating the disease process.
Keywords: Support vector machine, Meta-analysis, Data integration, TCGA
Introduction
Over the last decade, the technologies of microarray and massively parallel sequencing
generate multiple omics sources from a large cohort at an unprecedented rate. Besides,
since the experimental costs have dropped, a huge amount of data sets have been accu-
mulated in public data repositories (e.g., Gene Expression Omnibus (GEO) and Sequence
Read Archive (SRA)). And yet low reproducibility has been a chronic concern due to mid-
and-small size of each individual experimental unit (e.g., 40–100) and low signal-to-noise
ratios of genomic expression data [24, 26, 27]. In an effort to tackling these challenges,
effective data integration methods have been widely spotlighted in biomedical research
[2]. The traditional meta-analysis integrates significance levels or effect sizes of similar
data sets (similar design or biological hypothesis), and has proven to be effective in dis-
covering significant biomarkers [14, 37]. Multi-study data integration is also known as
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“horizontal meta-analysis” that combines multiple homogeneous omics data [38]. More-
over, many large consortia such as the Cancer GenomeAtlas (TCGA) and LungGenomics
Research Consortium (LGRC) have generated different types of omics data (e.g., mRNA,
methylation, CNV and so on) using samples from a single cohort. Datasets are aligned ver-
tically by samples, and thus integration of such multi-omics data is called “vertical omics
integrative analysis” [38]. Jointly leveragingmulti-layers of omics data, vertical omics inte-
gration facilitates deciphering biological processes, capturing the interplay of multi-level
genomic features, and elucidating how a priori knowledge of biological information (e.g.,
pathway database) functions within the framework of systems biology.
Generally high-throughput microarray and sequencing data have been extensively
applied to monitor biomarkers and biological processes related to many diseases [4], to
predict complex diseases (e.g., cancer diagnosis, [36]), prognosis [45], and therapeutic
outcomes [23]. In particular, the recent classification and prediction tools have notably
advanced the translational and clinical applications (e.g. MammaPrint [43]), Oncotype
DX [30] and Breast Cancer Index BCI [49]. In this trend, the support vector machine
(SVM) has been also popularly applied to many genomic applications and proved as one
of the most powerful prediction methods [3, 15, 29] attributed to unmatched flexibility
of non-linear decision boundary. Commonly gene selection (a.k.a. feature reduction) per-
taining to outcomes diminishes the dimension of expression data, enabling to shorten the
training time and to enhance interpretability. In addition, gene selection removes a large
number of irrelevant genes that potentially undermine precise prediction, and notably the
idea of feature selection using SVMs can extend to the setting of multi-omics data analysis
([18, 25]). As this concern related, many researchers have put tremendous efforts to cir-
cumvent low accuracy of the SVMs when analyzing high-dimensional genomic data. For
instance, Brown et al. [5] introduced a functional gene classification including the usage of
various similarity functions (e.g., kernels modeling prior knowledge of genes). Moreover,
as SVM takes on the small subset of samples that differentiate between class labels with
an exclusion of the remaining samples, it is believed to have the potential to handle large
feature spaces and the ability to identify outliers. Guyon et al. [9] also proposed a gene
selection method that utilizes the SVM based on Recursive Feature Elimination (RFE)
recursively removing insignificant features to increase classification performance. In spite
of SVM’s outstanding fortes in many applications, the current SVMs are only focused
towards single data analysis, and so inevitably run into the problem of low reproducibil-
ity. To address this problem, we propose a meta-analytic framework based on the support
vector machine (Meta-SVM). The proposed Meta-SVM is motivated by the recent meta-
analytic method exploiting the meta-analytic logistic regression (Meta-logistic; [22]). To
our best knowledge, no method has been introduced, which extends the SVMs to com-
bining multiple studies in a meta-analytic fashion. Related to this, we develop a novel
implementation strategy in spirit of Newton’s method to estimate parameters of theMeta-
SVM. It is commonplace that the objective function of SVM is formed with the hinge
loss and a range of penalty terms (e.g., L1-lasso, group lasso and etcs). Importantly we,
however, adopts the sparse group lasso technique (i.e., both L1-lasso and group lasso,
simultaneously) to capture both common and study specific genetic effects across all stud-
ies. The proposed method, on this ground, achieves the identical purpose of rOP [41]
and AW [21], meta-logistic [22] whose feature selection allows to detect specific effects.
In genomic applications, it cannot be emphasized enough that data integration analysis
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has proved its practical utility and has become commonplace to identify key regulators
of cancer. Thus, many have paid attention to credible validation strategies that build on
multiple studies [7, 35]. Besides, meta-analysis essentially aids to adjust tissue specific
effects possibly distorting the analysis of individual datasets [21]. The optimization strat-
egy to estimate, therefore, focuses on how to maneuver these two terms (L1-lasso and
group lasso) in the formula. To overcome some of known traditional optimization rules
(e.g., linear and quadratic programming), which mostly entails heavy computing tasks,
we propose an approximation method to relax computational complexity in favor of con-
cise implementation. The idea is to approximate the hinge loss including but not limited
to penalty terms by a quadratic form, and thereby we can apply the classical coordinate
descent algorithm to optimize the whole objective function.
The paper is outlined as follows. In Methods section, we introduce the meta-analytic
method that builds on the support vector machine (Meta-SVM) and its implementation
strategy at length. Simulation studies section shows experimental studies to benchmark
performance of feature detection under various experimental scenarios. In Applications
to real genomic data section, we demonstrate the advantages of Meta-SVM in two real
data applications using publicly available omics data, and concluding remarks are pre-
sented in Concluding remark section. An R package “metaSVM” is publicly available
online at author’s github page (https://sites.google.com/site/sunghwanshome/).
Methods
Meta-analytic support vector machine (Meta-SVM)
Consider M independent studies, consisting of n(m) subjects of m-th study for 1 ≤ m ≤








be a vector, each
containing p common variables of the i-th subject for 1 ≤ i ≤ n(m) and 1 ≤ m ≤ M.




























j for 1 ≤ i ≤ n(m) and β(m) =(
β
(m)








, this is typically known as
the linear support vector machine. And our major interest is to estimate the solution of
β(m) that minimizes (1). By extension, in pursuit of integrating theM studies to a unified
model, we propose the meta-analytic support vector machine that builds onmultiple data
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)2 comes into play to integrate the effect size of the j-th variable
across M data sets. Of note, the L1 lasso penalty encourages the sparsity within a group
that potentially circumvents the all-in and all-out fashion. Thus, this property is in line
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withmeta-analytic feature selection even when heterogeneous studies are present in anal-
ysis, since the sparse group lasso allows to accommodate both common effects across all







be the sparse group lasso estimator of the meta-analytic support vector machine form-th
study for 1 ≤ m ≤ M.
Implementation strategy
For estimating β , the SVM traditionally exploits the linear or quadratic programming
well-suited to SVM’s dual problem. To our best knowledge, no coordinate descent-type
optimization has yet been proposed to address the sparse group lasso problem despite
the coordinate-type approach’s utility for implementation. The coordinate descent algo-
rithm is one of themost popular algorithms that are built on the convexity assumption. To
apply this algorithm to (2), an approximation to the smooth objective function is required
on account of the non-differential property of the hinge loss and the group lasso penalty.
With a little of algebraic trick, the group lasso penalty can be made twice-differentiable.
Precisely, we add some sufficiently small constant inside the square root, in the way that
the first and second derivative of the L1-lasso and group lasso penalty terms can be made
at β(m)j = 0. When it comes to the non-differential hinge loss, Zhang et al. [48] pro-
posed the successive quadratic algorithm (SQA): a generalization of Newton’s method
for unconstrained optimization such that it finds a step away from the current point of
iteration by minimizing a quadratic approximation of the problem. Taken together, the
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where β(m)∗ is an estimated coefficient vector at the current point for 1 ≤ m ≤ M.
Contrary to (2), Q˜λ1,λ2(β) is differentiable with respect to β , convex and separable with
respect to all of variables so that we can apply the coordinate descent algorithm by means

































and iterate for 1 ≤ j ≤ p and 1 ≤ m ≤ M until convergence. More details are provided in
Appendix.
Simulation studies
To evaluate the performance of the proposed Meta-SVMmethod in the genomic setting,
we simulated expression profiles with arbitrary correlated gene structures and variable
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effect sizes as follows: Simulate gene correlation structure for P = 30 genes, N = 20
samples in each study, and M = 3. In each study, 10 out of 30 genes belong to C = 2
independent clusters.
Step 1: Randomly sample gene cluster labels of 30 genes (Cp ∈ {0, 1, 2} and 1 ≤ p ≤ P),
such that C = 2 clusters each containing 5 genes are generated
(Pp=11(Cp = c) = 5, 1 ≤ c ≤ C = 2) and the remaining 20 genes are unclustered
genes (Pp=11(Cp = 0) = 20).




∗ ∼ W−1(ψ , 60), where ψ = 0.5I5×5 + 0.5J5×5,W−1 denotes the inverse
Wishart distribution, I is the identity matrix and J is the matrix with all the





. Calculate (m)c such that σ (m)c (m)c σ (m)c
 = (m)c ∗ .
Step 3: Denote by p(c)1 , · · · , p(c)5 as the indices for genes in cluster c. In other words,





, · · · ,X(m)
p(c)5 n
) ∼ MVN(0,R(m)c ), where 1 ≤ n ≤ N = 20, 1 ≤ m ≤ M
and R is an arbitrary constant for adjusting of total variance (R = 1 as default).
Sample expression for unclustered genes X(m)pn ∼ N(0,R) for 1 ≤ n ≤ N and
1 ≤ m ≤ M if Cp = 0.
Step 4: To simulate differential expression pattern, sample effect sizes μ(m)p from
Unif (0.1, 0.5) for 1 ≤ p ≤ 10 as differential expression (DE) genes and set
μ
(m)
p = 0 for 11 ≤ p ≤ P as non-DE genes.
Step 5: For the first 10 control samples, Y (m)pn = X(m)pn (1 ≤ p ≤ P, 1 ≤ n ≤ N/2 = 10,
1 ≤ m ≤ M). For cases,
Y (m)p(n+10) = X(m)p(n+10) + μ(m)p (1 ≤ p ≤ P, 1 ≤ n ≤ N/2 = 10, 1 ≤ m ≤ M).
All tuning parameters (λ1 and λ2) are chosen by cross-validation, and the simulations
were repeated 50 times. Table 1 summarizes the results of all simulation studies. It is note-
worthy that the Meta-SVM achieves higher Youden index (= sensitivity + specificity −1)
compare to the meta-logistic regression model across all experimental scenarios (i.e.,
Table 1 Shown are the results of experimental studies to compare the meta-logistic model with the
meta-analytic SVM
Meta-SVM Meta-logistic regression
Variance (R) Sensitivity (SE) Specificity (SE) Youden Sensitivity (SE) Specificity (SE) Youden
No inclusion of random study
0.1 0.828 (0.001) 0.9843 (0) 1.812 0.1073 (0) 1 (0) 1.107
0.3 0.8127 (0.002) 0.8707 (0.001) 1.683 0.2087 (0.001) 0.996 (0) 1.205
0.5 0.76 (0.002) 0.867 (0.001) 1.627 0.2633 (0.001) 0.9123 (0.001) 1.176
Inclusion of one random study
0.1 0.8007 (0.011) 0.9837 (0.002) 1.784 0.102 (0.004) 0.997 (0.001) 1.099
0.3 0.6673 (0.013) 0.8497 (0.009) 1.517 0.2113 (0.009) 0.966 (0.005) 1.177
0.5 0.6013 (0.017) 0.852 (0.009) 1.453 0.2527 (0.01) 0.8667 (0.008) 1.119
Inclusion of two random studies
0.1 0.624 (0.016) 0.9737 (0.009) 1.598 0.0847 (0.005) 0.994 (0.001) 1.079
0.3 0.51 (0.016) 0.8433 (0.006) 1.353 0.1727 (0.011) 0.9317 (0.005) 1.104
0.5 0.4167 (0.012) 0.85 (0.009) 1.267 0.256 (0.012) 0.8193 (0.006) 1.075
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R = 0.1, 0.3 and 0.5), and thus this suggests the Meta-SVM performs better in identifying
the true signal features. Given that the meta-logistics model results in low sensitivity, the
meta-logistic model has a tendency to overly penalize the effect size of features. In con-
trast, when data are sampled with low variance (R = 0.1), specificity of the meta-logistic
model is shown to be a little higher than that of theMeta-SVM (e.g., 1, 0.997 and 0.994 for
the Meta-logistic, and 0.9843, 0.9837 and 0.9737 for the Meta-SVM), and yet the meta-
logistic model still suffers low sensitivity at the expense of high specificity. Inspired by
the simulation design introduced by meta-analysis of rth ordered p-value (rOP) [41], we
also designed simulation schemes such that only a few studies provide major signals that
differentiate binary outcomes like real data. To this end, we replaced signal genes of one
or two studies with complete random noise (i.e., sampled from N(0,R); no signal genes).
This leads to only one or two signal genes, respectively, among three data sets. Under
this simulation scenario, the Meta-SVM still performs better as in Table 1, presenting
higher Youden index than the meta-logistic model no matter how many random noises
are imposed.
Applications to real genomic data
In this section, we apply the Meta-SVM methods to two real examples of idiopathic
pulmonary fibrosis expression profiles (IPF; 221 samples in four studies of binary out-
come (i.e., case and control)) and breast cancer expression profiles provided by The
Cancer Genome Atlas (TCGA) including mRNA, copy number variation (CNV) and
epigenetic DNA methylation (http://cancergenome.nih.gov/; 300 samples of estrogen
receptor binary outcome (i.e., ER+ and ER-)). It should be noticed that we integrate in
the first application (IPF) four homogeneous studies in a fashion of horizontal integra-
tion, whereas we align in the second application (breast cancer) three genomic data by the
common cohort in the context of vertical integration. Integrating multilevel-omics data
is reasonable, in that inter-regulation flows in systems biology are present from CNV to
mRNA and from DNA methylation to mRNA [16]. Therefore, these inter-omics features
aligned on identical protein coding regions can be jointly estimated in the group lasso.
Table 2 outlines the data descriptions, for a total of seven data sets and source references.
In the pre-processing stage, genes and DNA methylation probes were matched across
homogeneous studies and multi-omics data, and centered with scaling. Non-expressed
and/or non-informative genes were filtered according to the rank sum of mean intensities
and variances across studies. Importantly noted is that this filtering procedure has been
used in a previous meta-analysis work [47] and this filtering step is unbiased since class
labels are not involved in the process. This generated 110 common genes in IPF study
Table 2 Shown are the brief descriptions of the eight microarray datasets of disease-related binary
phenotypes (e.g., case and control). All datasets are publicly available
Name Study Type # of samples Control Case Reference
TCGA breast cancer mRNA 300 234 (ER+) 66 (ER-) The Cancer Genome Atlas (TCGA)
TCGA breast cancer Methylation 300 234 (ER+) 66 (ER-) The Cancer Genome Atlas (TCGA)
TCGA breast cancer CNV 300 234 (ER+) 66 (ER-) The Cancer Genome Atlas (TCGA)
KangA (batch 1) IPF mRNA 63 11 52 Kang et al (2012). GSE47460
KangB (batch 2) IPF mRNA 96 21 75 Kang et al. (2012) GSE47460
Konishi IPF mRNA 38 15 23 Konishi et al. (2009), GSE10667
Pardo IPF mRNA 24 11 13 Pardo et al. (2005), GSE2052
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and 108 common genes and matched methylation probes in TCGA for down-stream
prediction analysis.
We applied gene set enrichment analysis to TCGA breast cancer data to figure out if
our identified gene sets are in line with underlying biological pathways from the KEGG
database [12]. It is notable that the identified gene set of the TCGA multiple omics data
in Table 3 is significantly enriched in the ABC transporters pathways, which is already
well-known to be correlated to breast cancer mechanisms, particularly related to estro-
gen receptor and drug resistance [8, 28]. To our surprise, the ABC transporters pathway
is considerably relevant to breast cancer mechanisms in many ways. For instance, breast
cancer resistance protein (BCRP) is an ATP-binding cassette (ABC) transporter known
as a molecular cause of multidrug resistance (MDR) in diverse cancer cells [46]. Besides
Nakanishi et al. [28] discovered that up-regulation of BCRPmRNA expression was shown
in estrogen receptor (ER)-positive breast cancer. This identified pathway has been con-
sistently verified as critical for cancer outcomes and sensitivity to therapeutic treatments
[8, 19]. In previous study under the similar design [10], ABCC8 and ABCC11 in Table 3
are believed to be modifiers of progression and response to the chemotherapy of breast
cancer.
Generally idiopathic pulmonary fibrosis (IPF) is one of fatal lung diseases with a poor
prognosis. Thus, it is quite imperative to monitor potential predictors of outcome. The
original studies in Table 2 [17, 32] posed a hypothesis on molecular biomarkers associ-
ated with IPF, and presented differentially expressed (DE) genes that distinguish IPF and
control patients. For instance, Konishi et al. [17] identified in qRT-PCRmicroarray exper-
iments MMP7, AGER andMMP7 are significantly higher and AGER is significantly lower
in IPF. Pardo et al. [32] also pointed out that MMP7 is more significantly overexpressed
compared with control lungs. Note that Meta-SVM is shown to be consistent with known
evidence as detecting AGER and MMP7. Our findings in Table 3 also include CCL18.
Importantly, it has been repeatedly reported that expression of CCL18 relates to course
of pulmonary function parameters in patients with pulmonary fibrosis [33, 34]. However,
there was a little discrepancy regarding the roles of CCL18 according to the previous stud-
ies [31, 33]. And yet, since theMeta-SVM incorporates multiple data together, we can still
give more credence to CCL18 as a molecular biomarker to predict IPF.
Of the 33 identified genes of IPF data (See Table 3 and Additional file 1: Table S1),
we further reduce the number of genes for post-hoc analysis by exploring significant
gene modules, equivalently gene-gene interaction, via Netbox [6]. NetBox is an analytic
software well-suited to detect connecting genes to a network, identifying statistically sig-
nificant “linker” genes on the basis of four public data sources: NCI-Nature Pathway
Table 3 This table includes selected features of multiple omics data via the Meta-SVM
Four studies of lung disease (IPF)
C20orf114 MMP7 CXCL14 AGER TMEM100 THY1 CXCL2 HSD17B6 CCL18 CPA3 GEM
LEPREL1 ANXA3 CYP1B1 LRRC32 EMP2 FHL2 ADM C7 ITGA7 IGFBP2 BACE2 FKBP11
RGS5 FCGR3A SRPX FBLN2 HPCAL1 SOX4 CD248 CLDN5 LTBP1 ALOX5AP
Three multi-omics data of breast cancer (TCGA)
ABCC11 ABCC8 ACOX2 CAMP CST9L GRPR LAMP3 LCN2 LTF
MUCL1 NME5 THRSP VTCN1
- This gene set is significantly enriched in the ABC transporters (KEGG)
(FDR adjusted p-value = 0.025).
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Interaction Database [40], Human Protein Reference Database [13], MSKCC Cancer Cell
Map (http://www.mskcc.org/), and Reactome [11]. We implemented gene-gene interac-
tion analysis, and successfully detected four gene modules, each of which constitutes
mutually correlated genes. Additional file 1: Figure S1 displays the structure of combined
networks based on four distinct gene modules. Focusing on the genes that belong to the
four modules, we examine on MMP7 [32, 44, 50] , LTBP1 [20] , FHL2 [1] , CXCL2 [42],
THY1 [39] and AGER [17] to confirm whether or not these are associated with IPF (See
Additional file 1: Table S3). MMP7 is traditionally thought of as the predictive signature
since MMP7 of IPF patients is among the molecules that are more significantly overex-
pressed compared with control lungs [32]. More interestingly, Bauer et al. [1] identified
a novel set of 12 disease-relevant translational gene markers including FHL2, MMP7
that are able to separate almost all patients with IPF from control subjects in multiple
large-scale cohorts. Related to CXCL2, [42] investigated the pathogenesis of pulmonary
fibrosis relevant to the imbalance in the expression of these angiogenic and angiostatic
CXC chemokines. This study demonstrates in the bleomycin model that the amount of
CXCL2 is found positively correlated with measures of fibrosis. When it comes to novel
therapeutic targets, profiling DNA methylation changes to fibrosis has been increasingly
spotlighted by observing hypomethylation of oncogene promoters. In doing so, Sanders
et al. [39] reported that hypermethylation epigenetically decreases THY1 (See Additional
file 1: Table S3) in IPF fibroblasts as IPF suppressor genes. Taken together, the Meta-SVM
is found to be efficient in identifying potential biomarkers that facilitate elucidating the
disease process.
Concluding remark
In this article, we introduce a meta-analytic framework using the support vector machine.
The objective function of Meta-SVM applies the hinge loss and the sparse group lasso,
and so we also develop a novel strategy for implementing the sparse group lasso in the
context of Newton’s method. More importantly, the proposed Meta-SVM shows many
advantages in discovering the underlying true signals and in detecting gene sets enriched
for cancer disease process validated as biologically significant. Putting all things together,
we conclude that the proposed meta-SVM is a reasonable choice to effectively achieve
the common aims of meta-analysis. This is not that surprising given that the Meta-SVM
takes advantages of the meta-analytic design that jointly leverages multiple omics data.
For future study, we may improve computational speed via low-level programming lan-
guages (e.g., C/C++ or Fortran) since coordinate descent algorithm sometimes leads to
heavy computation due to slow convergence at the exchange of the straightforward algo-
rithm structure. Usage of diverse kernels (e.g., quadratic and radial basis kernels) can be
a possible choice to improve performance of feature discovery, and prediction accuracy.
Moreover, it is worthwhile to impose interaction terms in the model, making it possible
to account for the complex association among genomic features. We leave these ideas for
future tasks.
Appendix
Optimization of a penalized univariate quadratic function
Univariate Lasso problem
Consider a quadratic function q defined as
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q(z) = b2 (z − c)
2 + d for z ∈ R,
where b > 0 and c, d ∈ R. Let qλ be a penalized quadratic function given as





Note that b = q′′(z) ∀z ∈ R and c = argminz∈Rq(z) since c is the solution to q′(z) = 0.










y − λ if y > λ
y + λ if y < −λ
0 if
∣∣y∣∣ ≤ λ
for y ∈ R and λ > 0.
Univariate Sparse group lasso problem
Let
qλ1,λ2(z) = b2 (z − c)
2 + λ1
√
z2 + d + λ2|z| for z ∈ R, (6)
where b > 0, d ≥ 0 and c ∈ R. If d = 0, then the univariate sparse group lasso problem
becomes the univariate lasso problem. Equivalently,
qλ1,λ2(z) = b2 (z − c)
2 + (λ1 + λ2)|z| for z ∈ R
and we have
zλ1,λ2 = ST (c, (λ1 + λ2)/b) .
Consider the univariate sparse group lasso problem with d > 0. Let Fs(z) be the form






An approximation to qλ1,λ2 is
q˜λ1,λ2(z) = b2 (z − c)
2 + λ1
√
z2 + d + λ2
∫ z
−∞
Fs(u)du for z ∈ R.




Using the Newton-Raphson method, we can find z˜λ1,λ2 . Note
dq˜λ1,λ2(z)
dz = b(z − c) + λ1
z√
z2 + d + λ2Fs(z) for z ∈ R
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and
d2q˜λ1,λ2(z)




z2 + d)3 + λ2ws(z) for z ∈ R
where
ws(z) = 12sFs(z) (1 + Fs(z)) .
Starting from an initial value z(0), we iterate
z(t+1) = z(t) − dq˜
λ1,λ2(z(t))/dz
d2q˜λ1,λ2(z(t))/dz2 .
Implementation for the meta-analytic SVM
In order to estimate the solution of β(m), we approximate (3) to the univariate quadratic
function, and then apply the Newton-Raphson method. To derive the quadratic form, we
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where β(m)∗ is an estimated coefficient vector at the current point. The quadratic form
























is an univariate sparse group quadratic function of the form (6)
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dj = ∑k =j β(m)
2
k and a sufficiently small positive constant  for 1 ≤ j ≤ p. We propose
the following algorithm to solve the meta-analytic SVM via Newton’s method in a fashion
of coordinate descent algorithm:
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Table 4 An algorithm for the meta-analytic SVM via Newton’s method
Step 1: For 1 ≤ m ≤ M, set the initial value β(m)(0) .






































for 0 ≤ j ≤ p and 1 ≤ m ≤ M.
Step 3: Update t = t + 1 and go to Step 2 until convergence.
Additional file
Additional file 1: Table S1. The Meta-SVM’s coefficient of lung disease mRNA data. Table S2. The Meta-SVM’s
coefficient of TCGA breast cancer multi-level omics data. Table S3. Gene-gene interaction analysis using 33 identified
genes of IPF mRNA data. Figure S1. Gene networks that display the relationships among significant genes. The
orange nodes are the selected linker genes out of 33 genes in Table 3. The blue nodes indicate linker genes not
presented in the original input list, but are significantly connected to members of the input list. (DOCX 187 kb)
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